Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, Share, Trends, Growth and Forecast 2025

Duchenne Muscular Dystrophy (DMD) Therapeutics Market

Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Type (Small Molecules and Biologics): Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 - 2025

Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-5242 Published Date: Feb-2020 Status : Published
Market Size in 2018 Market Forecast in 2025 CAGR (in %) Base Year
USD 2.36 Billion USD 20.56 Billion 36.3% 2019

Duchenne Muscular Dystrophy (DMD) Thera Market

Market Overview

According to the report, global demand for Duchenne Muscular Dystrophy (DMD) therapeutics market was valued at approximately USD 2.36 Billion in 2018, and is expected to generate revenue of around USD 20.56 Billion by end of 2025, growing at a CAGR of around 36.3% between 2019 and 2025.

The report covers forecast and analysis for the Duchenne Muscular Dystrophy (DMD) therapeutics market on a global and regional level. The study provides historic data from 2016 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the Duchenne Muscular Dystrophy (DMD) therapeutics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Duchenne Muscular Dystrophy (DMD) therapeutics market on a global as well as regional level.

In order to give the users of this report a comprehensive view on the Duchenne Muscular Dystrophy (DMD) therapeutics market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein type segment is benchmarked based on their market size, growth rate and general attractiveness.

Global Duchenne Muscular Dystrophy (DMD) Therapeutics MarketRequest Free Sample

The report provides company market share analysis in order to give a broader overview of the key players in the Duchenne Muscular Dystrophy (DMD) therapeutics market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the Duchenne Muscular Dystrophy (DMD) therapeutics market on global and regional basis.

Duchenne muscular dystrophy is a harsh kind of muscular dystrophy. The indication of muscle weakness typically begins at the age of four in boys and deteriorates rapidly. Most of the affected people are incapable of walking by the age of 12. The affected muscles tend to look bigger because of augmented fat content. Constant research efforts in comprehending the etiology of Duchenne muscular dystrophy gave way to the recognition of the dystrophin gene that is accountable for coding patients.

Factors such as growing funding for research and development activities and technological advancements in diagnostic techniques will act as major driving factors in the growth of global Duchenne Muscular Dystrophy (DMD) therapeutics market. Efforts taken by governments and non-government organizations to create awareness will act as an opportunity for the market players in the Duchenne Muscular Dystrophy (DMD) therapeutics market. Nonetheless, lack of awareness and dearth of skilled researchers will restrict the growth of global Duchenne Muscular Dystrophy (DMD) therapeutics market.

Application Segment Analysis Preview

The global Duchenne Muscular Dystrophy (DMD) therapeutics market has been split into type and region. Based on type, Duchenne Muscular Dystrophy (DMD) therapeutics market has been segmented into small molecules and biologics. The biologics segment accounted for the highest market share in 2018 due to ongoing research on biologics and anticipated launch of biologics currently in late phases of clinical trials.

Regional Analysis Preview

North America will be the leading region during the forecast period. High investment in research and development of Duchenne Muscular Dystrophy (DMD) therapeutics and presence of major manufacturers will boost the market growth in this region. Europe is expected to be the second major market. The key reasons are efforts taken by health agencies and advantageous reimbursement scenario. Asia Pacific will grow at rapid rate over the forecast time-frame due to increasing investment in research and development to develop new products. The market in Latin America will grow at a substantial rate during the estimate period. The Africa and Middle Eastern region is expected to exhibit definite progression in the anticipated time-frame.

Duchenne Muscular Dystrophy (DMD) Therapeutics Market : Report Scope

Report Attributes Report Details
Report Name Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Report
Market Size in 2018 USD 2.36 Billion
Market Forecast in 2025 USD 20.56 Billion
Growth Rate CAGR of 36.3%
Number of Pages 188
Forecast Units Value (USD Billion), and Volume (Units)
Key Companies Covered PTC Therapeutics Inc., F. Hoffmann-La Roche Ltd., Santhera Pharmaceuticals, Wave Life Sciences Ltd., and Sarepta Therapeutics Inc. among others.
Segments Covered By Type and By Region.
Base Year 2019
Historical Year 2015 to 2018
Forecast Year 2019 - 2025
Customization Scope Avail customized purchase options to meet your exact research needs. Request For Customization

Key Market Players & Competitive Landscape

The report also includes detailed profiles of key players such as :

  • PTC Therapeutics Inc.
  • F. Hoffmann-La Roche Ltd.
  • Santhera Pharmaceuticals
  • Wave Life Sciences Ltd.
  • and Sarepta Therapeutics Inc.

This report segments the Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market as follows:

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market: By Type

  • Small Molecules
  • Biologics

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market: By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

Methodology

FrequentlyAsked Questions

global demand for Duchenne Muscular Dystrophy (DMD) therapeutics market was valued at approximately USD 2.36 Billion in 2018, and is expected to generate revenue of around USD 20.56 Billion by end of 2025

PTC Therapeutics Inc., F. Hoffmann-La Roche Ltd., Santhera Pharmaceuticals, Wave Life Sciences Ltd., and Sarepta Therapeutics Inc. among others.

Choose License Type

  • zion payment modes

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed